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SUMMARY
Lymphocytes are cells circulating between the blood and tissues. It has been stated that a correlation 
exists between immune infi ltrate and breast cancer. These tumours are infi ltrated by T cells, B cells, 
natural killer cells and macrophages. The infi ltrating T cells are of helper (CD4+) and cytotoxic (CD8+) 
phenotypes. Specifi c immunity mediated by cytolytic T lymphocytes is suspected of playing an anti-
cancer role. It is widely known that regional lymph nodes are an important immunological defence 
or “barrier” against tumour expansion. Some authors have reported that in cancer patients natural 
killer (NK) cells and CD8+ T cells are diminished in regional lymph nodes, particularly those involved 
by the tumour. 
In the presented study the authors review current knowledge on this problem and the possibility of 
using successful immunotherapy with monoclonal antibodies for breast cancer.
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Lymphocytes are mobile cells, continuously 
recirculating between the blood and tissues, 
returning to the blood via the lymphatic sys-
tem. It has been stated that peripheral blood 
contains approximately 2% of all lympho-
cytes. The rest of these cells can be found in 
lymphatic organs, namely the tonsils, spleen, 
young thymus and, especially, lymph nodes 
[1].
The correlation between immune infi ltrate 
and breast cancer has been widely investigat-
ed since the early work of Black [2]. Several 
studies have stated that these tumours are 
infi ltrated by a heterogeneous population of 
immune cells, namely T cells, B cells, natu-
ral killer (NK) cells and macrophages [3]. 
Tumour infi ltrating lymphocytes (TIL) are 
of helper (CD4+) and cytotoxic (CD8+) pheno-
types, and express activation markers such 
as CD25 and the transferrin receptor [4]. Tu-
mour-infi ltrating lymphocytes are able to pro-
duce and release vascular endothelial growth 
factor (VEGF) and basic fi broblastic growth 
factor, which can induce lymphangiogenesis 
and angiogenesis and consequently could per-
mit the dissemination of cancer cells through 
lymphatics to regional lymph nodes [5]. An-
titumour effects are mediated through the 
induction of a CD8+ T cell response against 
a specifi c antigen. Cytotoxic CD8+ lympho-
cytes and NK cells bind with the Fas ligand 
and cause tumour cell death. TIL can interact 
with tumour antigen and cause direct or indi-
rect cell lysis by releasing cytokines such as: 
interferon g (INF-g), tumour necrosis factor a 
(TNF-a), and granulocyte colony-stimulating 
factor (GM-CSF).
Functionally T cells lack antibody-depen-
dent cellular cytotoxicity and show no or low 
natural killer (NK) activity [6]. A quantitative 
assessment of cell-mediated immunity is the 
measurement of subpopulations of T-helper 
and T-suppressor lymphocytes. Impaired 
cellular immunity can be associated with a 
depressed CD4/CD8 ratio. The exact rela-
tion between the effi cacy of T cell-dependent 
immune mechanisms or between the extent 
and type of lymphocyte infi ltration and tu-
mour progression in carcinoma of the breast 
is a matter of debate [7,8]. This interrelation 
is suspected of determining the infl uence of 
the immune system on the pathogenesis and 
progression of breast cancer [9]. Activity of 
tumour-infi ltrating lymphocytes is impaired 
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by inhibitory cytokines, increased regulatory 
T lymphocyte reaction, tumour cell MHC mol-
ecule alterations, and aberrant Fas ligand ex-
pression [10]. 
Adaptive immunity is mediated by anti-
bodies and by CD4+ and CD8+ T cells, and it 
usually exploits an indirect pathway, termed 
cross-priming, to achieve initial recognition 
of cancers [11]. Specifi c immunity mediated 
by cytolytic T lymphocytes is suspected of 
playing an anticancer role. Nevertheless, tu-
mours have developed various mechanisms 
such as downregulation, mutation, or loss of 
HLA class I molecules to escape from T-cell-
based immune surveillance [12]. It is widely 
known that regional lymph nodes are capable 
of being an important immunological defence 
or “barrier” against tumour expansion [13]. 
Several studies have reported that removal 
of uninvolved lymph nodes might have a dev-
astating effect on the immunological defence 
of the host against systemic metastasis or tu-
mour recurrence [14]. Some authors have re-
ported that in cancer patients natural killer 
(NK) cells and CD8+ T cells are diminished 
in regional lymph nodes, particularly in the 
lymph nodes with tumour involvement [15, 
16]. Nodal status as determined by pathologi-
cal examination of lymph nodes has been com-
monly shown to be the single most important 
predictor of survival in breast cancer [17, 18]. 
A direct relationship between the risk of dis-
tant recurrence and number of involved axil-
lary nodes has been established [19]. Wong et 
al. [20] demonstrated that the tumour-infi l-
trating lymphocytes of patients with positive 
lymph nodes had greater tumoricidal activity. 
In an analysis of the peripheral blood and 
axillary lymph nodes of 40 breast carcinoma 
patients, Whitfort et al. [15] demonstrated 
that while there was little difference in the 
overall proportions of T and B lymphocytes, 
there was a larger CD4+ helper T cell popula-
tion in regional nodes that had been invaded 
by cancer. Rubbert et al. [16] also showed 
a decline of CD8+ T cells in regional lymph 
nodes, particularly in lymph nodes with can-
cer involvement in breast carcinoma patients. 
These data indicate that draining lymph nodes 
of cancer patients may host specifi c or non-
specifi c suppression of NK cells and CD8+ T 
cells, which seems to be responsible for their 
poor immunological activity. Battaglia et al. 
[21] tried to determine the distribution of a 
diverse lymphocyte population in normal hu-
man lymph nodes in comparison with corre-
sponding peripheral blood. In their study they 
examined uninvolved lymph nodes in an early 
stage of cervical or endometrial cancer and 
benign diseases. The authors found that CD4+ 
lymphocytes were equally represented in both 
lymph nodes and peripheral blood, whereas 
CD8+ lymphocytes were much less numerous 
in lymph nodes. Consequently the CD4+/CD8+ 
ratio in lymph nodes was almost twice that 
of peripheral blood. Natural killer cells were 
<2%. 
Georgiannos et al. [22] noted marked varia-
tion in intensity of the infi ltrate between indi-
vidual cancers of 60 examined patients with 
breast cancer with over 90% of tumours hav-
ing a moderate or intense infi ltrate. T-helper 
(CD4+) and cytotoxic T cells (CD8+) were 
found in all primary tumours, but without vis-
ible distribution dependency within individual 
tumours. The infi ltrate changed from one that 
was CD4+ predominant to one that was cyto-
toxic CD8+ predominant. Analyzing the as-
sociation between the characteristics of the 
immune infi ltrate and established markers of 
prognosis they reached signifi cance only in 
the intensity of the infi ltrate of TIL cells and 
the number of positive lymph nodes and with 
ER (oestrogen receptor) expression, but not 
with PR (progesterone receptor) expression. 
Dadmarz et al. [23] separated tumour in-
fi ltrating lymphocytes from breast tumours, 
metastatic lymph nodes and malignant pleural 
effusions from 34 patients with breast cancer. 
In addition to screening bulk TIL cultures, 
cells were separated into CD4+ and CD8+ 
subsets and extensively studied. Three CD4+ 
TIL lines were found to secrete signifi cant 
amounts of GM-CSF and TNFa. In contrast 
to the CD4+ T cells, the CD8+ TIL cells did 
not secrete TNFa, but they did secrete GM-
CSF when cultured with autologous tumour 
without presence of other stimulators. In the 
study of Kohrt et al. [24] percentage analysis 
of nodes involved by breast tumour and mag-
nitude of CD4 and CD8 changes did not show 
a statistically signifi cant relationship. These 
observations oppose a simple linear relation-
ship between immune alterations and tumour 
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invasion, but suggest that actually tumour in-
vasion can be preceded by dynamic changes 
in the immune profi le within tumour-draining 
lymph nodes. 
Macchetti et al. [9] used fl ow cytometry to 
analyse the tumour-infi ltrating leukocytes of 
breast cancer patients with T1 to T2 breast 
tumours in an attempt to correlate phenotypi-
cal markers of tumour-infi ltrating leukocytes 
with axillary lymph node status. The surface 
characteristics were determined by using 
preparations of monoclonal antibodies which 
allowed the lymphocytes to be phenotyped as 
T cells, B cells, CD4+ T cells, CD8+ T cells, or 
NK cells respectively. In patients with lymph 
node metastasis, an increased mean percent-
age of tumour-infi ltrating CD4+ T cells, but 
not CD8+ T cells, was observed which was cor-
related with worse prognosis.
Although TIL are activated in most breast 
cancers, implying recognition of tumour anti-
gen, cell-mediated immunity is obviously in-
complete. This may emphasize the potential 
role of immunotherapy for breast cancer and 
suggest that it may succeed in targeted pa-
tients, especially those with minimal residual 
disease. Lindencrona et al. [25] showed that 
HER-2 specifi c tumour immunity after DNA 
vaccination by plasmid (HER-2 and CM-CSF) 
relied completely on both CD4 and CD8 T 
cells, and that anti-HER-2 antibodies were not 
necessary to elicit a protective antitumour im-
mune response.
Successful immunotherapy as a form of 
adjuvant therapy for breast cancer relies on 
the demonstration that cell-mediated immu-
nity against tumour cells remains functional 
[26]. The antitumour effects in therapy by 
cytokines (GM-CSF) were mediated through 
the induction of a CD8+ T cell response [27]. 
However, it is not certain that this infi ltrate is 
necessarily present in an anti-neoplastic role. 
Presence of class II antigens in tumour cells 
could enhance the immune response against 
the tumour through the ability to present an-
tigens, or by stimulating the proliferation of 
allogenic lymphocytes through the generation 
of allospecifi c cytotoxic T lymphocytes. It is 
now possible to manipulate immunological ef-
fector cells or antigen-presenting cells ex vivo 
in order to induce an effective antitumour re-
sponse. Numerous attempts using autologous 
breast cancer cells and tumour infi ltrating/
associated lymphocytes (TIL/TAL) have been 
made to identify breast cancer associated an-
tigens but they were not fully successful [28]. 
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